ADMA Biologics, Inc.
ADMAADMA BioLogics, Inc. is a biopharmaceutical company specializing in the development and commercialization of immunoglobulin and other plasma-derived therapies. Focused on providing targeted treatments for immune deficiencies and infectious diseases, the company operates manufacturing facilities and has a portfolio aimed at improving patient outcomes through innovative plasma-based biologics.
Company News
ADMA Biologics faces a class action securities fraud lawsuit alleging the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth. A March 2026 report revealed ADMA induced distributors to stock excess inventory through rebates and extended payment terms, resulting in a 29.1% stock pri...
A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suf...
Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing p...
Rosen Law Firm reminds investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of the August 10, 2026 deadline to join a securities class action lawsuit. The firm alleges that ADMA made false statements regarding undisclosed related-party transactions, channel stuffing practices, inadequate internal controls, and misleading revenue representations durin...
Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing p...
